← Eichor
Study identifier: NCT04795882 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A New Study Evaluating the Activity of Modular CAR T for mYeloma

Condition: Multiple Myeloma  ·  Sponsor: University College, London

PhasePhase 1
Planned participants27
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma. The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.

This description comes directly from the study's public registry record.

Talk to the study team

MCARTY Trial Coordinator  ·  02076799599  ·  ctc.MCARTY@ucl.ac.uk

Lydia Lee

Always discuss trial participation with your own doctor first.

Locations (1)

University College London HospitalLondon, County (Optional), United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04795882